dexibuprofen

Small moleculeexperimental

Dexibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). It is the active dextrorotatory enantiomer of ibuprofen. Most ibuprofen formulations, as well as other drugs of the profen drug class, contain a racemic mixture of both isomers. — Wikipedia

Clinical trial activity

17 trials · 17 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
6
Phase 3
2
Phase 4
9

Earliest trial started Feb 1, 2008 (NCT00812422)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Mol. weight
352.48 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • dexibuprofen
  • dexibuprofen
  • dexibuprofen
  • dexibuprofen
  • dexibuprofen
  • dexibuprofen
  • dexibuprofen
  • dexibuprofen
  • d-ibuproten
  • d-ibuproten
  • neoprofen
  • neoprofen
  • neoprofen
  • rufen
  • rufen
  • seractil
  • seractil
  • s-ibuprofen
  • s-ibuprofen
  • (+)-(s)-p-isobutylhydratropic acid
  • (+)-(s)-p-isobutylhydratropic acid
  • (s)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
  • (s)-α-methyl-4-(2-methylpropyl)benzeneacetic acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04772781Phase 2Dec 31, 2021Apsen Farmaceutica S.A.
NCT04637529Phase 2Jul 31, 2021Apsen Farmaceutica S.A.
NCT03852459Phase 2Jan 12, 2018Aponia Laboratories, Inc., JBR Clinical Research
NCT02956525Phase 1Jun 1, 2017Apsen Farmaceutica S.A., Azidus
NCT02956512Phase 1Jun 1, 2017Apsen Farmaceutica S.A., Azidus
NCT02929147Phase 4Nov 1, 2016Istanbul University
NCT02373514Phase 4Jan 1, 2015Akdeniz University, Pamukkale University
NCT02324985Phase 2Jan 1, 2015Aponia Laboratories, Inc., Lotus Clinical Research
NCT02285972Phase 4Nov 1, 2014T.C. Ordu Universitesi
NCT02159547Phase 4May 1, 2014Akdeniz University, Antalya Training and Govermental Hospital
NCT02018601Phase 4Sep 1, 2013Complexo Hospitalario Universitario de A Coruña
NCT02602197Phase 3Aug 1, 2013Baskent University
NCT02568735Phase 4Jan 1, 2013Kuopio University Hospital
NCT01730326Phase 4Mar 1, 2012Pamukkale University
NCT01422291Phase 4Jan 1, 2011Pamukkale University
NCT01066676Phase 4Oct 1, 2009Gebro Pharma GmbH, Rehabilitationszentrum, Bad Hofgastein
NCT00812422Phase 3Feb 1, 2008Inje University, Seoul National University
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Apsen Farmaceutica S.A.For profit4422017
Pamukkale UniversityAcademic/Hospital3212011
Akdeniz UniversityAcademic/Hospital2212014
Aponia Laboratories, Inc.For profit2212015
AzidusFor profit2012017
Antalya Training and Govermental HospitalAcademic/Hospital1012014
Baskent UniversityAcademic/Hospital1112013
Complexo Hospitalario Universitario de A CoruñaAcademic/Hospital1112013
Gebro Pharma GmbHFor profit1112009
Inje UniversityAcademic/Hospital1112008
Istanbul UniversityAcademic/Hospital1112016
JBR Clinical ResearchFor profit1012018
Kuopio University HospitalAcademic/Hospital1112013
Lotus Clinical ResearchFor profit1012015
Rehabilitationszentrum, Bad HofgasteinAcademic/Hospital1012009
Seoul National UniversityAcademic/Hospital1012008
T.C. Ordu UniversitesiAcademic/Hospital1112014
17 organizations
Page 1 / 1